The ACME Laboratories Ltd. announced that their product "Chlorzoxazone 500 mg tablet" which was manufactured from Solid Dosage Unit (SDU-Unit 2) of the Company and submitted to US FDA, has been approved by US Food & Drug Administration (US FDA) as per the section 505 (j) of the Federal Food, Drug and Cosmetic Act (FD&C ACT). The company has also informed that this prestigious accreditation will enable them to export products to the US market.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
69 BDT | +1.32% | +5.34% | -18.82% |
1st Jan change | Capi. | |
---|---|---|
-18.82% | 124M | |
+55.32% | 815B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- ACMELAB Stock
- News The ACME Laboratories Ltd.
- The ACME Laboratories Ltd. Announces US FDA approval for "Chlorzoxazone tablet" of the Company